Paraoxonase 1 (PON1) Polymorphisms, Haplotypes and Activity in Predicting CAD Risk in North-West Indian Punjabis
暂无分享,去创建一个
Kiran Dip Gill | Yash Paul Sharma | K. Gill | Y. Sharma | Surjit Singh | Nidhi Gupta | Surjit Singh | V. Nagarjuna Maturu | N. Gupta | V. Maturu
[1] Coronary artery disease in South Asians. Second meeting of the International Working Group. 16 March 1997, Anaheim, California. , 1998, Indian heart journal.
[2] Robert Barouki,et al. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. , 2003, Molecular pharmacology.
[3] G. Jarvik,et al. Polymorphisms in the human paraoxonase (PON1) promoter. , 2001, Pharmacogenetics.
[4] K. Bainey,et al. Coronary Artery Disease in South Asians , 2012, Cardiology in review.
[5] G. Jarvik,et al. Determination of Paraoxonase 1 Status Without the Use of Toxic Organophosphate Substrates , 2008, Circulation. Cardiovascular genetics.
[6] J. Ott,et al. Power and Sample Size Calculations for Case-Control Genetic Association Tests when Errors Are Present: Application to Single Nucleotide Polymorphisms , 2002, Human Heredity.
[7] J. Miller,et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. , 1998, Atherosclerosis.
[8] P. Durrington,et al. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon , 1997, British journal of pharmacology.
[9] R. Hegele,et al. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[10] M. Meyer,et al. Multiplex amplification of ancient DNA , 2006, Nature Protocols.
[11] P. McElduff,et al. Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study , 2003, Circulation.
[12] J. Ferrières,et al. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease , 2000, European journal of clinical investigation.
[13] V. Steen,et al. CYP2D6 multiallelism. , 1996, Methods in enzymology.
[14] C. Furlong,et al. Purification of rabbit and human serum paraoxonase. , 1991, Biochemistry.
[15] T. Suehiro,et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. , 1996, International journal of cardiology.
[16] M. Najafi,et al. Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. , 2009, Thrombosis research.
[17] J. Danesh,et al. Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies , 2004, The Lancet.
[18] R. Singh,et al. The modernization of Asia. Implications for coronary heart disease. Council on Arteriosclerosis of the International Society and Federation of Cardiology. , 1996, Circulation.
[19] R. Schmidt,et al. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. , 1998, Stroke.
[20] C. Furlong,et al. Determination of paraoxonase (PON1) status requires more than genotyping. , 1999, Pharmacogenetics.
[21] Dan S. Tawfik,et al. The 'evolvability' of promiscuous protein functions , 2005, Nature Genetics.
[22] P. Winocour,et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. , 1991, Atherosclerosis.
[23] I. Leviev,et al. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[24] P. Malhotra,et al. Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. , 1996, Indian heart journal.
[25] E. Birman-Deych,et al. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. , 2003, Environmental health perspectives.
[26] C. Walker,et al. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. , 1986, Clinical chemistry.
[27] P. Elwood,et al. Structural and functional analysis of the human KB cell folate receptor gene P4 promoter: cooperation of three clustered Sp1-binding sites with initiator region for basal promoter activity. , 1995, Biochemistry.
[28] R. Singh. Coronary artery disease in South Asians. , 1997, Indian heart journal.
[29] A. Montali,et al. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[30] S. Deakin,et al. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. , 2003, The Biochemical journal.
[31] D. Shih,et al. Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis* , 2000, The Journal of Biological Chemistry.
[32] M. Keifer,et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.
[33] N. Holland,et al. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity , 2006, Pharmacogenetics and genomics.
[34] O. Lockridge,et al. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[35] B. La Du,et al. The human serum paraoxonase/arylesterase polymorphism. , 1983, American journal of human genetics.
[36] D. Sanghera,et al. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[37] M. Blatter,et al. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. , 1993, European journal of biochemistry.
[38] A. Smolen,et al. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. , 1991, Drug metabolism and disposition: the biological fate of chemicals.
[39] C. Abbott,et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. , 1994, The Biochemical journal.
[40] Surjit Singh,et al. Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus. , 2007, The Indian journal of medical research.
[41] M. Jauhiainen,et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. , 1996, The Journal of clinical investigation.
[42] A. Todd,et al. Prospective Study of Blood and Tibia Lead in Women Undergoing Surgical Menopause , 2004, Environmental health perspectives.
[43] P. Durrington,et al. Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[44] T. Zama,et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[45] P. Froguel,et al. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. , 2000, Diabetes.
[46] P. Moulin,et al. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism. , 1999, Journal of lipid research.
[47] Aldons J Lusis,et al. Thematic review series: The Pathogenesis of Atherosclerosis Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.R400001-JLR200 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL , 2004, Journal of Lipid Research.
[48] A. Smolen,et al. PURIFICATION OF HUMAN SERUM PARAOXONASE/ARYLESTERASE , 1991 .
[49] C. Carlson,et al. Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[50] L. Hsu,et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. , 1998, Atherosclerosis.
[51] P. Durrington,et al. The paraoxonase gene family and coronary heart disease , 2002, Current opinion in lipidology.
[52] Y. Ikeda,et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. , 2000, Atherosclerosis.
[53] G. Charpentier,et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes , 1995, The Lancet.
[54] V. Steen,et al. [22] CYP2D6 multiallelism , 1996 .
[55] J. Hokanson,et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[56] P. Durrington,et al. How high-density lipoprotein protects against the effects of lipid peroxidation , 2000, Current opinion in lipidology.
[57] T. Parrón,et al. Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure , 2003, Human & experimental toxicology.
[58] M. Marmot,et al. Association of Early‐Onset Coronary Heart Disease in South Asian Men With Glucose Intolerance and Hyperinsulinemia , 1993, Circulation.
[59] S. Malcolm,et al. Genotype to phenotype , 2001 .
[60] A. Montali,et al. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population , 2002, European journal of clinical investigation.
[61] G. Jarvik,et al. Paraoxonase 1 status as a risk factor for disease or exposure. , 2010, Advances in experimental medicine and biology.
[62] D. Shih,et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.
[63] G. Schellenberg,et al. Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.